parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in bergmann glia	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	5 Parkinson's papers of 460	0.76
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 11304

NDRG2 in dopamine neurons, braak+0.16 (p 0.685) → -0.37 (p 0.329)receipt 11312
NDRG2 in astrocytes, braak+0.29 (p 0.456) → -0.10 (p 0.802)receipt 11311

receipt 11312: NDRG2 in dopamine neurons, braak

power: full sample -0.02 (p 0.935, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.04 (p 0.874, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.01 (p 0.969, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.13, sign flips 5; without severely affected donors -0.02 (p 0.935, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NDRG2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 11311: NDRG2 in astrocytes, braak

power: full sample +0.06 (p 0.800, n 18), 95% CI -0.42 to +0.52. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.10 (p 0.696, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.10 (p 0.696, n 18). could be the mix.
skeptic: leave-one-out range -0.09 to +0.15, sign flips 3; without severely affected donors +0.06 (p 0.800, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NDRG2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts